NEUROCRINE BIOSCIENCES, INC.
- Country
- πΈπͺSweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 24
- Registration Number
- NCT03792672
- Locations
- π³π±
CHDR, Leiden, Netherlands
Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
- Conditions
- Parkinson's Disease
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 14
- Registration Number
- NCT03733496
- Locations
- πΊπΈ
Emory University, Atlanta, Georgia, United States
πΊπΈUniversity of California, San Francisco, San Francisco, California, United States
πΊπΈOhio State University, Columbus, Ohio, United States
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 6
- Registration Number
- NCT03732534
- Locations
- π΅π·
Neurocrine Clinical Site, San Juan, Puerto Rico
A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 16
- Registration Number
- NCT03706469
- Locations
- πΊπΈ
Celerion, Lincoln, Nebraska, United States
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
- Conditions
- Tardive Dyskinesia (TD)
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 89
- Registration Number
- NCT03698331
- Locations
- π΅π·
Neurocrine Clinical Site, San Juan, Puerto Rico
Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 40
- Registration Number
- NCT03687684
- Locations
- π―π΅
Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
- Conditions
- Parkinson's Disease
- Interventions
- Other: Sham (Placebo) Surgery
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 14
- Registration Number
- NCT03562494
- Locations
- πΊπΈ
UC Irvine, Irvine, California, United States
πΊπΈUniversity of Philadelphia, Dept of Neurology, Philadelphia, Pennsylvania, United States
πΊπΈNorthwestern Medical Faculty Foundation, Chicago, Illinois, United States
Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
- Conditions
- Tourette Syndrome
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 81
- Registration Number
- NCT03530293
- Locations
- πΊπΈ
Neuricrine Clinical Site, Sun City, Arizona, United States
π΅π·Neurocrine Clinical Site, San Juan, Puerto Rico
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 18
- Registration Number
- NCT03525886
- Locations
- πΊπΈ
Neurocrine Clinical Site, Seattle, Washington, United States
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 16
- Registration Number
- NCT03496870
- Locations
- πΊπΈ
Neurocrine Clinical Site, Farmington Hills, Michigan, United States